Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lisa Fraleigh

Psychiatry Logan, UT Doctor of Osteopathy

NPI 1558478115 CMS profile 1261016

112 E 100 N, Suite A, Logan, UT 84321

Open in the dashboard

General payments

$7,769

338 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lisa Fraleigh of Logan, UT is reported in the CMS Open Payments database as having received $7,769 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $970 53
2024 General $3,188 51
2023 General $889 44
2022 General $681 39
2021 General $776 51
2020 General $680 45
2019 General $585 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Fraleigh
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lisa Fraleigh were reported at $970. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lisa Fraleigh Psychiatry median Middle half National median
2019 $585 $184 $59–$605 $163
2020 $680 $119 $36–$372 $114
2021 $776 $143 $43–$576 $132
2022 $681 $153 $50–$590 $149
2023 $889 $170 $56–$651 $160
2024 $3,188 $179 $57–$673 $164
2025 $970 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neuronetics, Inc. $2,024 7 payments
  2. Otsuka America Pharmaceutical, Inc. $1,229 86 payments
  3. Supernus Pharmaceuticals, Inc. $841 35 payments
  4. Teva Pharmaceuticals USA, Inc. $806 35 payments
  5. AbbVie, Inc. $377 28 payments
  6. Neurocrine Biosciences, Inc. $335 18 payments
  7. Janssen Pharmaceuticals, Inc $326 16 payments
  8. Sunovion Pharmaceuticals Inc. $278 25 payments
  9. Ironshore Pharmaceuticals Inc. $259 14 payments
  10. ITI, Inc. $214 11 payments
  11. Other $1,080 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,367 332 payments
  2. Travel and Lodging $1,085 1 payment
  3. Education $317 5 payments
Products named General payments · program years 2019–2025
  1. Neurostar TMS Therapy System $2,016 6 payments
  2. REXULTI $895 59 payments
  3. Qelbree $701 25 payments
  4. VRAYLAR $377 28 payments
  5. Austedo XR $343 18 payments
  6. ABILIFY MAINTENA $301 24 payments
  7. LATUDA $278 25 payments
  8. INGREZZA $267 14 payments
  9. SPRAVATO $240 11 payments
  10. Azstarys $200 11 payments
  11. Other $2,186 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

336

Median for Psychiatry & Neurology: 100

Drug cost

$6,699

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14.3%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lisdexamfetamine Dimesylate Generic 13 $2,279
Ziprasidone Hcl Generic 28 $1,011
Trazodone Hcl Generic 55 $965
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 18 $417
Bupropion Xl Bupropion Hcl Brand 14 $416
Quetiapine Fumarate Generic 22 $336
Lorazepam Generic 12 $312
Sertraline Hcl Generic 23 $197
Duloxetine Hcl Generic 29 $155
Lithium Carbonate Generic 13 $149

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $558
$558 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $183
  • Lundbeck LLC $54
$237 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $142
$142 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $107
$107 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record